YIM Session 2: Translational Research of CAR T-Cells

Chair(s)

• 

  William Wierda, MD, PhD

  Professor of Medicine
  University of Texas MD Anderson Cancer Center
  Houston, TX, United States

Presentations:

• 9:35 AM – 9:45 AM EDT

  Combining CD19 CAR T cells with T cell-engaging bispecific antibody treatment enhances efficacy in murine models of CLL and ex vivo patient cultures
  

  Primary Author; Presenting Author: Alessia Floerchinger, MSc – German Cancer Research Center (DKFZ) Heidelberg

  Co-Author: Berit J. Brinkmann, PhD – University of Heidelberg

  Co-Author: Tobias Roider, MD – University of Heidelberg

  Co-Author: Peter-Martin Bruch, MD – University of Heidelberg

  Co-Author: Antonia Angeli, M.Sc. – University of Heidelberg

  Co-Author: Sibylle Ohl, N/A – German Cancer Research Center

  Co-Author: Norman Mack, N/A – German Cancer Research Center

  Co-Author: Mariana Coelho, PhD – German Cancer Research Center

  Co-Author: Philipp M. Roessner, MD – German Cancer Research Center

  Co-Author: Sascha Dietrich, MD – University of Duesseldorf

  Co-Author: Martina Seiffert, PhD – German Cancer Research Center
• 9:45 AM – 9:55 AM EDT

  Expression of SIGLEC-10 ligands CD24 and CD52 limit T cell and CAR-T cell function in CLL
  

  Primary Author: Jaco A.C. Van Bruggen, PhD – Amsterdam University Medical Centers

  Co-Author; Presenting Author: Fleur S. Peters, PhD – Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam

  Co-Author: Gaspard Cretenet, PhD – 1 Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam institute for Infection and Immunity, Amsterdam, The Netherlands; 2 Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands

  Co-Author: Perry D. Moerland, PhD – Amsterdam University Medical Centers

  Co-Author: Aldo Jongejan, PhD – Amsterdam University Medical Centers

  Co-Author: J. Joseph Melenhorst, PhD – Cleveland Clinic,Center for Immunotherapy & Precision Immuno-Oncology

  Co-Author: Gerritje J.W. van der Windt, PhD – Amsterdam University Medical Centers

  Co-Author: Eric Eldering, PhD – 1 Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam institute for Infection and Immunity

  Co-Author: Arnon P. Kater, MD, PhD – Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam
• 9:55 AM – 10:05 AM EDT

  Generation and preclinical evaluation of a novel ROR1-specific CAR T-cells against chronic lymphocytic leukemia
  

  Primary Author; Presenting Author: Md Kamrul Hasan, PhD – Center for Novel Therapeutics, Moores Cancer Center, University of California San Diego

  Co-Author: Christopher Oh, BS – Center for Novel Therapeutics, Moores Cancer Center, University of California San Diego

  Co-Author: Christina Girgis, BS – Center for Novel Therapeutics, Moores Cancer Center, University of California San Diego

  Co-Author: George Widhopf, PhD – Center for Novel Therapeutics, Moores Cancer Center, University of California San Diego

  Co-Author: Charles Prussak, PhD – Center for Novel Therapeutics, Moores Cancer Center, University of California San Diego

  Co-Author: Thomas J. Kipps, MD, PhD – Center for Novel Therapeutics, Moores Cancer Center, University of California San Diego
• 10:05 AM – 10:15 AM EDT

  Session 2: Panel Discussion